Under pressure: Advances in device‐based heart failure therapy for patients with preserved or mildly reduced ejection fraction

European Journal of Heart FailureEarly View Invited Editorial Under pressure: Advances in device-based heart failure therapy for patients with preserved or mildly reduced ejection fraction Lukas Stolz, Corresponding Author Lukas Stolz [email protected] Medizinische Klinik und Poliklinik I, LMU Klinikum, LMU München, Munich, Germany German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany Corresponding author. Medizinische Klinik und Poliklinik I, LMU Klinikum, LMU München, D-81377 Munich, Germany. Tel: +49 1525 4889915, Fax: +49 89 440078870, Email: [email protected]Search for more papers by this authorJörg Hausleiter, Jörg Hausleiter Medizinische Klinik und Poliklinik I, LMU Klinikum, LMU München, Munich, Germany German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, GermanySearch for more papers by this author Lukas Stolz, Corresponding Author Lukas Stolz [email protected] Medizinische Klinik und Poliklinik I, LMU Klinikum, LMU München, Munich, Germany German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany Corresponding author. Medizinische Klinik und Poliklinik I, LMU Klinikum, LMU München, D-81377 Munich, Germany. Tel: +49 1525 4889915, Fax: +49 89 440078870, Email: [email protected]Search for more papers by this authorJörg Hausleiter, Jörg Hausleiter Medizinische Klinik und Poliklinik I, LMU Klinikum, LMU München, Munich, Germany German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, GermanySearch for more papers by this author First published: 03 May 2024 https://doi.org/10.1002/ejhf.3277 The opinions expressed in this article are not necessarily those of the Editors of the European Journal of Heart Failure or of the European Society of Cardiology. doi: 10.1002/ejhf.3241. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol 2017; 14: 591–602. https://doi.org/10.1038/nrcardio.2017.65 10.1038/nrcardio.2017.65 PubMedWeb of Science®Google Scholar 2Riccardi M, Tomasoni D, Vizzardi E, Metra M, Adamo M. Device-based percutaneous treatments to decompress the left atrium in heart failure with preserved ejection fraction. Heart Fail Rev 2023; 28: 315–330. https://doi.org/10.1007/s10741-022-10280-4 10.1007/s10741?022?10280?4 PubMedWeb of Science®Google Scholar 3Tromp J, Kosiborod MN, Angermann CE, Collins SP, Teerlink JR, Ponikowski P, et al. Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction – Results from the EMPULSE trial. Eur J Heart Fail. https://doi.org/10.1002/ejhf.3218 Published online ahead of print 04/04/24. 10.1002/ejhf.3218 Google Scholar 4Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al.; EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021; 385: 1451–1461. https://doi.org/10.1056/NEJMoa2107038 10.1056/NEJMoa2107038 CASPubMedWeb of Science®Google Scholar 5Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al.; DELIVER Trial Committees and Investigators. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 2022; 387: 1089–1098. https://doi.org/10.1056/NEJMoa2206286 10.1056/NEJMoa2206286 PubMedWeb of Science®Google Scholar 6Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF, et al. SGLT-2 inhibitors in patients with heart failure: A comprehensive meta-analysis of five randomised controlled trials. Lancet 2022; 400: 757–767. https://doi.org/10.1016/s0140-6736(22)01429-5 10.1016/S0140-6736(22)01429-5 CASPubMedWeb of Science®Google Scholar 7Lauder L, Pereira TV, Degenhardt MC, Ewen S, Kulenthiran S, Coats AJS, et al. Feasibility and efficacy of transcatheter interatrial shunt devices for chronic heart failure: A systematic review and meta-analysis. Eur J Heart Fail 2021; 23: 1960–1970. https://doi.org/10.1002/ejhf.2360 10.1002/ejhf.2360 PubMedWeb of Science®Google Scholar 8Shah SJ, Borlaug BA, Chung ES, Cutlip DE, Debonnaire P, Fail PS, et al.; REDUCE LAP-HF II Investigators. Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): A randomised, multicentre, blinded, sham-controlled trial. Lancet 2022; 399: 1130–1140. https://doi.org/10.1016/s0140-6736(22)00016-2 10.1016/S0140-6736(22)00016-2 PubMedWeb of Science®Google Scholar 9Hibbert B, Zahr F, Simard T, Labinaz M, Nazer B, Sorajja P, et al.; ALT FLOW Investigators. Left atrial to coronary sinus shunting for treatment of symptomatic heart failure. JACC Cardiovasc Interv 2023; 16: 1369–1380. https://doi.org/10.1016/j.jcin.2023.03.012 10.1016/j.jcin.2023.03.012 PubMedWeb of Science®Google Scholar 10Urey MA, Hibbert B, Jorde U, Eckman P, Simard T, Labinaz M, et al. Left atrial to coronary sinus shunting for treatment of heart failure with mildly reduced or preserved ejection fraction: The ALT FLOW Early Feasibility Study 1-year results. Eur J Heart Fail. https://doi.org/10.1002/ejhf.3241 Published online ahead of print 12/04/24. 10.1002/ejhf.3241 Web of Science®Google Scholar 11Guimaraes L, Lindenfeld J, Sandoval J, Bayés-Genis A, Bernier M, Provencher S, et al. Interatrial shunting for heart failure: Current evidence and future perspectives. EuroIntervention 2019; 15: 164–171. https://doi.org/10.4244/eij-d-18-01211 10.4244/EIJ-D-18-01211 PubMedWeb of Science®Google Scholar 12Sorajja P, Whisenant B, Hamid N, Naik H, Makkar R, Tadros P, et al.; TRILUMINATE Pivotal Investigators. Transcatheter repair for patients with tricuspid regurgitation. N Engl J Med 2023; 388: 1833–1842. https://doi.org/10.1056/NEJMoa2300525 10.1056/NEJMoa2300525 PubMedWeb of Science®Google Scholar 13Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, et al.; COAPT Investigators. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med 2018; 379: 2307–2318. https://doi.org/10.1056/NEJMoa1806640 10.1056/NEJMoa1806640 PubMedWeb of Science®Google Scholar 14Garcia RA, Benton MC, Spertus JA. Patient-reported outcomes in patients with cardiomyopathy. Curr Cardiol Rep 2021; 23: 91. https://doi.org/10.1007/s11886-021-01511-5 10.1007/s11886-021-01511-5 PubMedWeb of Science®Google Scholar 15Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, et al.; PARTNER 2 Investigators. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med 2016; 374: 1609–1620. https://doi.org/10.1056/NEJMoa1514616 10.1056/NEJMoa1514616 CASPubMedWeb of Science®Google Scholar Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation